← Leaderboards
Sylvain Fleury
Texas Biomedical Research Institute
$4,868,148
Attributed
$4,868,148
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2019–23$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,629,269 · 2
By mechanism
U19$13,629,269 · 2
Top collaborators
- Ruth Margrit Ruprecht4 shared
- Donald Bruce Edwards1 shared
- Francois J Villinger1 shared
Most similar at Texas Biomedical Research Institute
Same institution · by research overlap
- Larry S. Schlesinger$102,133,846
- Jean L Patterson$4,362,807
- Anton M Sholukh$4,879,570
- Jason Liang$9,025
- Donald Bruce Edwards$0
Others in their field
Other Emerging Leaders on “Membrane”
- Ted Ross · University Of Georgia$71,962,304
- Gary Fanger · Rise Therapeutics, Llc$21,703,466
- Thomas Denny · Duke University$19,381,749
- Leonard Freedman · Leidos Biomedical Research, Inc.$15,756,756
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$10,599,402
- Mary E Hamby · Cognition Therapeutics, Inc.$9,832,688
Research focus
MembraneMucous MembraneFormulationImmunogenicityLeadManufacturing ProcessCollaborationsEpidemicImmunogenicImmunizationInfluenzaIntramuscularLiquid SubstanceMacaca MulattaAdjuvantBiomedical ResearchCapsuleDosage FormsCold ChainsHiv-1Hiv VaccineHiv Vaccine Trials NetworkAcquired Immunodeficiency SyndromeNeedles
Grant awards (12)
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,629,815
U19 · FY2023 · AI
Vaccine development and production$97,093
U19 · FY2023 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,615,853
U19 · FY2022 · AI
Vaccine development and production$1,529,201
U19 · FY2022 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,719,534
U19 · FY2021 · AI
Vaccine development and production$1,077,795
U19 · FY2021 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,855,534
U19 · FY2020 · AI
Vaccine development and production$938,754
U19 · FY2020 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,213,216
U19 · FY2019 · AI
Vaccine development and production$777,557
U19 · FY2019 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$727,169
U19 · FY2019 · AI
Vaccine development and production$447,748
U19 · FY2019 · AI · contact PI